Monday, 16 July 2018 - 2:01
  • it
  • de
  • en
  • fr

CAR-T

Chinese biotech sector, leader in CAR-T technology

China has clearly acquired an outstanding position in the CAR-T area, with 116 ongoing clinical trials, versus 96 in the US and 15 in Europe. Chinese researchers are obtaining positive results in the treatment of blood cancers considered incurable before…

Analysts don’t approve of Celgene’s takeover to Juno Therapeutics

Analysts are assessing Celgene’s potential takeover to Juno. Despite their different views, all experts agree that the acquisition will be very expensive ($8-$10bn) and will not provide any short-term solution to Juno’s issues. Juno Therapeutics offers Celgene the opportunity to…

Massachusetts, the cradle of modern biotechnology

Massachusetts seems to be the place in the world with the highest excitement for novel biotechnology, and is very likely to have the most important cluster of companies focusing on the development of novel therapies. What follows are some examples…

Business of CAR-T gene therapies for lymphoma heats up

Excitement among Investors in the CAR-T business mounted and shares of the companies focusing on CAR-T reacted yesterday as it was announced that Kite/Gilead’s CAR-T therapy Yescarta significantly increases–by 15.4 months–life expectancy of patients with lymphoma. Gilead’ shares rose over…

EMA: Novartis submits MAA for CAR-T therapy Kymriah

Novartis announced today that that it has submitted a MAA (Marketing Authorization Application) to EMA for CTL019 (tisagenlecleucel) for two different indications. Indeed, the application refers both to the treatment of children and young adults with B-cell ALL (acute lymphoblastic…

FDA approves Yescarta, Kite/Gilead’s CAR-T therapy

Kite, part of Gilead group, has announced that FDA has approved Yescarta (axicabtagene ciloleucel), a CAR-T (chimeric antigen receptor T cell) therapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines…

FDA approves Novartis’ Kymriah, first CAR-T therapy

Novartis announced that FDA has approved Kymriah (tisagenlecleucel – CTL019) suspension for intravenous infusion. Kymriah is the first CAR-T (Chimeric Antigen Receptor T cell) ever approved and is indicated for the treatment of refractory acute lymphoblastic leukemia (ALL) in adults…

Further details on $12bn takeover of Kite Pharma by Gilead

Gilead acquired California-based Kite Pharma for $11.9bn, that is a 29% premium over last Friday’s closing price and 66% over the company’s valuation 12 months ago. The acquisition makes Gilead the leader in CAR-T (Chimeric Antigen Receptor T) cell therapies,…

Gilead makes widely-anticipated move – Kite acquired for $11.9bn

Gilead announced today, before Wall Street opened, that it has acquired the biotech Kite Pharma Inc. for $11.9bn, corresponding to valuing the company at $180 per share, with a 29% premium to Friday’s closing price. Gilead’s investors had been urging…

CAR-T, Breakthrough Therapy Designation by FDA for Novartis’ therapy

Novartis announced today that FDA has granted Breakthrough Therapy designation to CTL019, an investigational CAR-T therapy, for the treatment of adult patients with relapsed and refractory DLBCL (diffuse large B-cell lymphoma), who have failed two or more prior therapies. This…

FDA grants priority review to Novartis’ CAR-T therapy

FDA granted priority review to CTL019, a CAR-T therapy developed for pediatric and young adult patients with B-cell acute lymphoblastic leukemia. Like all CAR-T therapies, the novel therapy by Novartis consists of CAR-T therapy, consists of engineering the patient’s T…

Kite’s CAR-T therapy development likely to speed up

Kite Pharma announced at an investor day presentation positive results from an interim analysis of its CAR-T product candidate—KTE-C19—suggesting it will be possible to submit the application for the treatment approval in a short time. In particular, ZUMA-1 Phase II…